Moderna, Inc.'s Q2 2025 earnings highlight a steep revenue decline post-pandemic, with just $0.1bn in revenue and a $(0.8bn) ...

Despite efforts to spare employees by scaling back R&D and reducing operating costs by roughly $1.5 billion over the next two ...

Moderna expects to have mNEXSPIKE available for eligible populations in the U.S. for the 2025-2026 respiratory virus season, alongside Spikevax and mRESVIA ®, the Company's approved respiratory ...